Shape Therapeutics and Roche have entered into a strategic collaboration and license agreement to develop RNA-based gene therapies for Parkinson’s, Alzheimer’s, and rare diseases. Under the terms of the agreement, Shape will use its proprietary RNA technologies to leverage molecular machinery already present in human cells to…
Patient dosing has been completed in the Phase 2a clinical trial testing ANVS401, Annovis Bio’s investigational therapy for Alzheimer’s disease and Parkinson’s disease. An additional 40 patients with Parkinson’s disease were treated with ANVS401, with the company now preparing to share final safety and efficacy data later this year. According to…
A new hydrogel matrix appears to ease the delivery of therapeutic stem cells into the brain, a necessary step in potentially using these cells to treat Parkinson’s disease. In animal models, this hydrogel was found to provide a safe scaffold for stem cells to differentiate into dopamine-producing nerve cells —…
Farnesol, a natural compound of some herbs and fruits in commercial use, was seen to protect nerve cells in the brain and possibly restore some of these cells to health in multiple mouse models of Parkinson’s disease. Specifically, the compound prevented the loss of dopamine-producing neurons — nerve cells…
Inhibikase Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to start a Phase 1 clinical trial evaluating its investigational, once-daily, oral medicine IkT-148009 in patients with Parkinson’s disease. The clearance comes after the agency reviewed the safety, tolerability and pharmacokinetic data from a Phase 1 study…
A committee of the European Medicines Agency (EMA) is recommending the refusal of marketing authorization for Nouryant (istradefylline) — approved as Nourianz in the U.S. — as a medication for treating off episodes in Parkinson’s disease in the EU. In its opinion, the Committee for Medicinal Products for Human…
A compound naturally found in turmeric essential oil, called aromatic turmerone (ar-turmerone), and its derivatives were seen to protect dopaminergic neurons in a tissue culture model of Parkinson’s, researchers report. These findings support the already known role of ar-turmerone in reducing the inflammatory response caused by activated microglia —…
Training to dance to music on a weekly basis may slow the progression of both motor and non-motor symptoms of Parkinson’s disease, a three-year study has found. Results from this pilot study suggest that dance training could be used as a strategy to slow the progression of Parkinson’s in…
Therapeutic Solutions International has filed a patent for the use of a type of immune cell, called a dendritic cell, to potentially treat Parkinson’s disease. The patent application includes data, obtained in an animal model, showing that dendritic cells obtained from umbilical cord blood have the potential to…
Smoking history may not influence the severity of symptoms in Parkinson’s disease, a small study suggests. Moreover, in some individuals, exposure to cigarette smoke may worsen motor symptoms, which could lead patients to quit smoking and explain why smoking is more common among people without the disease. The study,…
Get regular updates to your inbox.